201.18
+15.82(+8.53%)
Currency In USD
| Previous Close | 185.36 |
| Open | 187.01 |
| Day High | 202.41 |
| Day Low | 184.6 |
| 52-Week High | 202.41 |
| 52-Week Low | 110.04 |
| Volume | 3.4M |
| Average Volume | 1.98M |
| Market Cap | 29.51B |
| PE | 22.89 |
| EPS | 8.79 |
| Moving Average 50 Days | 177.52 |
| Moving Average 200 Days | 147.39 |
| Change | 15.82 |
If you invested $1000 in Biogen Inc. (BIIB) 10 years ago, it would be worth $804.75 as of February 09, 2026 at a share price of $201.18. Whereas If you bought $1000 worth of Biogen Inc. (BIIB) shares 5 years ago, it would be worth $747.02 as of February 09, 2026 at a share price of $201.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China
GlobeNewswire Inc.
9 hours ago
TOKYO and CAMBRIDGE, Mass., Feb. 08, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
GlobeNewswire Inc.
Feb 04, 2026 12:30 PM GMT
Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naïve individuals and those previously treated with 12 mg nusinersenThe high-dose regimen of nusinersen also slowed neurodegener
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
GlobeNewswire Inc.
Jan 28, 2026 12:30 PM GMT
Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease activityLitifilimab has the potential to be a first-in-class ther